Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

OICR-12694 is an inhibitor of Bcl-6.1 It binds to the BTB domain on Bcl-6 (Kd = 5 nM in a surface plasmon resonance (SPR) assay). OICR-12694 decreases transcription of Bcl-6-targeted genes in a reporter assay using SU-DHL-4 cells (EC50 = 89 nM). It reduces the proliferation of Karpas-422 large B cell lymphoma cells (IC50 = 92 nM).
WARNING This product is not for human or veterinary use.
1. Discovery of OICR12694: A novel, potent, selective, and orally bioavailable BCL6 BTB inhibitor. ACS Med. Chem. Lett. 14(2), 199-210 (2023).